Pharmaceuticals major Zydus Cadila on Saturday said that Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market an oral suspension of Oseltamivir powder, used for treatment and prevention of influenza.
"Zydus' Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Oseltamivir powder for oral suspension, 6 mg/ml... used in the treatment and prevention of influenza," the company said in a regulatory filing.
The drug will be produced at Nesher Pharmaceuticals' manufacturing facility located at St Louis, US, it said, adding that the sales of product are estimated at $367.92 million.
The group now has more than 150 approvals and has so far filed over 300 Abbreviated New Drug Applications (ANDAs) since the commencement of the company's filing process.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)